Racial and Ethnic Differences in Antiseizure Medications Among People With Epilepsy on Medicaid: A Case of Potential Inequities.

Neurol Clin Pract

Department of Population and Quantitative Health Sciences (WPB, THC, SMW, KCS, MS), School of Medicine, Case Western Reserve University, Cleveland, OH; Department of Neurology (GFBV), University Hospitals Cleveland Medical Center and School of Medicine, Case Western Reserve University, Cleveland, OH; AAMC Center for Health Justice (PMA), Association of American Medical Colleges, Washington, DC; Epilepsy Center of Excellence (OIK), Baltimore VA Medical Center, US Department of Veterans Affairs, MD; Department of Neurology and Geisel School of Medicine (BCJ), Dartmouth-Hitchcock Medical Center, Lebanon, NH; Center for Community Health Integration (KCS, MS), Department of Sociology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland; and Departments of Neurology and Psychiatry (SMK), University Hospitals Cleveland Medical Center and School of Medicine, Case Western Reserve University, OH.

Published: February 2023

Background And Objectives: Being on a newer, second-, and third-generation antiseizure medication (ASM) may represent an important marker of quality of care for people with epilepsy. We sought to examine whether there were racial/ethnic differences in their use.

Methods: Using Medicaid claims data, we identified the type and number of ASMs, as well as the adherence, for people with epilepsy over a 5-year period (2010-2014). We used multilevel logistic regression models to examine the association between newer-generation ASMs and adherence. We then examined whether there were racial/ethnic differences in ASM use in models adjusted for demographics, utilization, year, and comorbidities.

Results: Among 78,534 adults with epilepsy, 17,729 were Black, and 9,376 were Hispanic. Overall, 25.6% were on older ASMs, and being solely on second-generation ASMs during the study period was associated with better adherence (adjusted odds ratio: 1.17, 95% confidence interval [CI]: 1.11-1.23). Those who saw a neurologist (3.26, 95% CI: 3.13-3.41) or who were newly diagnosed (1.29, 95% CI: 1.16-1.42) had higher odds of being on newer ASMs. Importantly, Black (0.71, 95% CI: 0.68-0.75), Hispanic (0.93, 95% CI: 0.88-0.99), and Native Hawaiian and Other Pacific Island individuals (0.77, 95% CI: 0.67-0.88) had lower odds of being on newer ASMs when compared with White individuals.

Discussion: Generally, racial and ethnic minoritized people with epilepsy have lower odds of being on newer-generation ASMs. Greater adherence by people who were only on newer ASMs, their greater use among people seeing a neurologist, and the opportunity of a new diagnosis point to actionable leverage points for reducing inequities in epilepsy care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973322PMC
http://dx.doi.org/10.1212/CPJ.0000000000200101DOI Listing

Publication Analysis

Top Keywords

people epilepsy
16
newer asms
12
racial ethnic
8
racial/ethnic differences
8
asms
8
adherence people
8
newer-generation asms
8
odds newer
8
lower odds
8
asms greater
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!